Navigation Links
Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
Date:5/22/2012

FORT MYERS, Fla., May 22, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical announced today that Dr. Stan Headley has joined the company as Medical Director for its' PhenTabz and ADDTabz products. Dr. Headley brings over 15 years of experience to the world of Integrative Medicine. He holds a Doctorate of Medicine from Spartan Health Science University with clinical training in family medicine at Creighton University School of Medicine and St. Joseph's Hospital in Omaha, Nebraska.

Dr. Headley has served in various capacities in Natural Health as a clinical family medicine practitioner, Chief Medical Officer, Medical Director, Clinical Operations Manager, Natural Products Researcher, Product Training Educator and advocate as a guest speaker on various radio and television programs on Natural Health forums including International radio programs in Puerto Rico and Barbados.

"Dr. Headley's wealth of experience and industry knowledge has already made him a key addition to the Gentech Pharmaceutical family. We are extremely excited to have him as our Medical Director as we continue to grow. Our current products PhenTabz and ADDtabz and new innovations currently in development, paired with increasing demand from our customers led us to look for a skilled professional who understood the incredible opportunities in the field of designer pharmacological alternatives. We have found that professional in Dr. Stan Headley.", says Derek Vest, CEO.

About Gentech Pharmaceutical
Gentech Pharmaceutical applies the science of perfecting and improving current medications and OTC formulations/chemical structures to produce "designer pharmacological alternatives" without the side effects. This unique ability allows Gentech Pharmaceutical to produce the most therapeutically advanced and safe pharmacological products currently available. Gentech shares the most basic and sacred goals of the physicians whom they provide products to: improve the health and well-being of patients with the safest and most effective products available in PhenTabz and ADDTabz.

Press release submitted by SubmitPressRelease123.com

Media Contact: Mike Sharp Gentech Pharmaceutical, 888-666-1714, marketing@gentechpharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Gentech Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Steven Tonkinson, ... he has completed every year since it started in 2003. This year, he ran ... attention of fellow runners and NBA team the Miami Heat. , This Sunday, while ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... 2016 , ... US Sports Camps , official operators of Nike Yoga ... kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New England ... Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering ...
Breaking Medicine News(10 mins):